• Recruiting

NCT03756896: Phase 2: Carfilzomib, Pomalidomide, and Dexamethasone in High-Risk Myeloma

Updated: Jun 13

NCT03756896: Phase 2: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma

KPd

high risk myeloma maintenance therapy


Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma



This phase II trial studies how well carfilzomib, pomalidomide, and dexamethasone work in treating patients with high-risk multiple myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pomalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carfilzomib, pomalidomide, and dexamethasone may work better in treating patients with multiple myeloma.


Sponsor:

Emory University


Collaborator:

Amgen

 

ClinicalTrials.gov Identifier: NCT03756896


Official Title: Maintenance Therapy With Carfilzomib, Pomalidomide and Dexamethasone (CPd) in High-Risk Myeloma Patients: A Phase 2 Study With a Safety Run-In


First Posted : November 28, 2018


Click here for details on ClinicalTrials.gov

 

Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information


Pomalidomide: National Cancer Institute

Pomalidomide : MedlinePlus Drug Information


Carfilzomib : National Cancer Institute

Carfilzomib : MedlinePlus Drug Information

 

Drug: Carfilzomib

Drug: Dexamethasone

Drug: Pomalidomide

 

Location

United States, Georgia







Posts Archive